Thomas N. Sato

Thomas N. Sato (佐藤匠徳) is a prominent Japanese educator, entrepreneur, and biologist, whose research focuses on understanding molecular basis of cancer, cardiac disease and metabolic diseases by using a number of animal models including mice, zebrafish and fruit flies. He is also working to invent next-generation therapeutics for human diseases based on the stochastic basis of life and disease. He is currently director of the Thomas N. Sato BioMEC-X Laboratories at the Advanced Telecommunications Research Institute International (ATR) in Kyoto,[1] research director of the ERATO Sato Live Bio-forecasting project JST in Kyoto, scientific founder and chair of board of directors Karydo TherapeutiX, Inc,[2] professor of Virtual Human InformatiX Clinic in Nara, and affiliate professor at Centenary Institute in Sydney, Australia.[3][4][5] He is also a triathlete who competes at Ironman distance including Ironman Lake Placid, Ironman Japan, Ironman Coeur d’Alene.

Life

University of Tsukuba, Japan, BS 1985
Georgetown University, Graduate School of Biological Sciences/Neuroscience, Ph.D. 1988
Scripps Research Institute, Postdoctoral Fellow 1989-1990
Roche Institute of Molecular Biology, Assistant Member 1991-1995
Harvard Medical School, Assistant Professor 1995-1997
Univ. of Texas Southwestern Medical School, Associate Professor 1997-2001 (Tenured in 1999)
Univ. of Texas Southwestern Medical School, Professor 2002-2004
Weill Medical College of Cornell University, Professor 2005-2006
Weill Medical College of Cornell University, Joseph C. Hinsey Professor 2005-2009
Nara Institute of Science and Technology Graduate School of Biological Sciences, Japan, Professor 2009
Cornell University, Biomedical Engineering, Adjunct Professor 2009–2019
Centenary Institute, Sydney, Australia, Affiliate Professor 2009–present

Works

Discoveries of Tie1, Tie2, and angiopoietins, that play the key roles in the blood vessel formation.[6][7][8]

Awards

National Science Contest for Elementary School Students, 1st place winner, Japan, 1973
Cold Spring Harbor Summer Fellowship, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY 1998
American Heart Association, Established Investigator Award, USA 1998-2003
Japanese Endocrinology and Cardiovascular Society, Jokichi Takamine Research Award, Japan 2005
Listed among top 1% most cited authors for journals in Molecular Biology and Genetics 2006
Scientific Advisory Board Member, Surface Logix, Inc. 2006-2008

References

"The Thomas N. Sato Bio-MEC-X Laboratories". www.tnsl.atr.jp.
"Scientific Founder English | Karydo TherapeutiX, Inc" (in Japanese). Retrieved 28 February 2020.
"Laboratory of Biodynamics and Integrative Biology". Archived from the original on 2013-07-05. Retrieved 2013-07-23.
"NAIST-Biological Science, Biodynamics and Integrative Biology". Archived from the original on 2013-07-23. Retrieved 2013-07-23.
"The 1st International Symposium on Human InformatiX – X-Dimensional Human Informatics and Biology" (in Japanese). Retrieved 28 February 2020.
Sato TN, et al. (October 1993). "Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system". Proc. Natl. Acad. Sci. USA. 90 (20): 9355–9358. doi:10.1073/pnas.90.20.9355. PMC 47566. PMID 8415706.
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (Dec 1996). "Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis". Cell. 87 (7): 1171–1180. doi:10.1016/S0092-8674(00)81813-9. PMID 8980224.
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (July 1997). "Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis". Science. 277 (5322): 55–60. doi:10.1126/science.277.5322.55. PMID 9204896.

External links

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "The Thomas N. Sato Bio-MEC-X Laboratories". www.tnsl.atr.jp.

[2] "Scientific Founder English | Karydo TherapeutiX, Inc" (in Japanese). Retrieved 28 February 2020.

[3] "Laboratory of Biodynamics and Integrative Biology". Archived from the original on 2013-07-05. Retrieved 2013-07-23.

[4] "NAIST-Biological Science, Biodynamics and Integrative Biology". Archived from the original on 2013-07-23. Retrieved 2013-07-23.

[5] "The 1st International Symposium on Human InformatiX – X-Dimensional Human Informatics and Biology" (in Japanese). Retrieved 28 February 2020.

[pmid8415706-6] Sato TN, et al. (October 1993). "Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system". Proc. Natl. Acad. Sci. USA. 90 (20): 9355–9358. doi:10.1073/pnas.90.20.9355. PMC 47566. PMID 8415706.

[7] Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (Dec 1996). "Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis". Cell. 87 (7): 1171–1180. doi:10.1016/S0092-8674(00)81813-9. PMID 8980224.

[8] Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (July 1997). "Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis". Science. 277 (5322): 55–60. doi:10.1126/science.277.5322.55. PMID 9204896.